Vertex to Present at UBS Global Healthcare Conference on November 11, 2025
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that its leadership will participate in the UBS Global Healthcare Conference. Reshma Kewalramani, President and Chief Executive Officer, will participate in a fireside chat on Tuesday, November 11, 2025, at 10:15 a.m. ET. The discussion will offer investors and industry observers a timely update on Vertex’s strategic priorities, ongoing clinical programs, and the company’s outlook for its portfolio of transformative medicines.
What to Expect from the Fireside Chat
The fireside chat is positioned to provide insights into Vertex’s progress across its key therapeutic areas, including treatments for serious diseases such as cystic fibrosis, sickle cell disease, and transfusion-dependent beta thalassemia. While the company’s approved therapies already help patients around the world, Vertex continues to advance a robust clinical pipeline designed to address unmet medical needs and broaden the impact of its science-driven approach.
Investors should expect updates on Vertex’s ongoing clinical trials, potential pipeline milestones, and the company’s ongoing efforts to expand access to its medicines. As with all investor events, the presentation will be accompanied by a review of Vertex’s financial performance, development timelines, and strategic priorities over the near to medium term.
How to Watch the Event
A live webcast of management’s remarks will be available on Vertex’s website under the Investors section, News and Events. The webcast provides a convenient way for global audiences to hear directly from Vertex leadership. A replay of the conference webcast will be archived on Vertex’s site, ensuring that interested stakeholders can access the content after the event.
About Vertex
Vertex is a global biotechnology company focused on scientific innovation to create transformative medicines for people with serious diseases and conditions. The company’s approved therapies address cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain. Vertex also maintains a robust clinical pipeline across multiple modalities and disease areas where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, and myotonic dystrophy type 1.
Founded in 1989, Vertex is headquartered in Boston with international headquarters in London. The company maintains research and development sites and commercial offices across North America, Europe, Australia, Latin America, and the Middle East. Vertex has earned recognition as a leading employer, including 16 consecutive years on Science magazine’s Top Employers list and a spot on Fortune’s 100 Best Companies to Work For list. For company updates and more about Vertex’s history of innovation, visit www.vrtx.com or follow Vertex on LinkedIn, Facebook, Instagram, YouTube, and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251027128133/en/
Investor Contacts
Vertex Pharmaceuticals Incorporated
Investors: InvestorInfo@vrtx.com
